News – Proniras

Press Releases

Proniras Corporation Announces First Patient Enrolled in Phase 1 Clinical Trial for Opioid Withdrawal Syndrome

November 14, 2024

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

February 01, 2024

Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal

September 17, 2020

Accelerator Life Science Partners Launches Proniras Corporation to Support Development of Tezampanel in the Treatment of Seizure Disorders

April 27, 2018

Proniras Corporation Awarded Contract Worth Up to $89.5 Million from U.S. Biomedical Advanced Research and Development Authority to Develop Tezampanel as a Medical Countermeasure for Nerve Agent-Induced Seizures

April 27, 2018

In the News

Proniras Corp. launches in Seattle, scores $89.5 million contract to develop new seizure drug (Geekwire.com)

April 27, 2018